CLUSTER filed Jul 9, 2026 at 17:38 ET
Three Immunome insiders sold a total of ~$813K in open-market shares over a one-week window ending July 7, 2026, including the Chief Business Officer, the Chief Medical Officer, and a Director. Director Barchas Isaac alone sold ~$2.4M across two days (July 6–7), making this the dominant insider transaction. At ~0.03% of Immunome's $2.7B market cap, the total sales are trivial in proportional terms, and cluster sales are weak directional signals per the academic literature. The sales are best interpreted as routine portfolio diversification, not a bearish corporate signal.